Ana María Linas-Alonso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana María Linas-Alonso has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Antoni Gilabert-Perramon
Department of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Government of Catalonia, Barcelona, Spain
1 shared publication - Arlet Puigferrat Campderrós
Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra (UPF), Barcelona, Spain, Spain
1 shared publication - Francesc López Seguí
Department of Epidemiology and Evaluation, Hospital del Mar, Barcelona, Catalonia; Center for Research in Health and Economics, Pompeu Fabra University, Barcelona, Catalonia; Chair in ICT and Health, Centre for Health and Social Care Research (CESS), University of Vic-Central University of Catalonia (UVic-UCC), Vic, Catalonia
1 shared publication - Glòria Merino Pinto
Centre de Recerca en Economia i Salut, Departament d'Economia i Empresa, Universitat Pompeu Fabra, Barcelona, 08005, Spain
1 shared publication - Jaume Viñas-I-Tarradas
Centre de Recerca en Economia i Salut, Universitat Pompeu Fabra, Spain
1 shared publication - Miguel Cainzos-Achirica
Department of Cardiology, Hospital del Mar, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 27 February 2026
- Published by MDPI AG in Preprints.org
Cost-Effectiveness of a Nurse-Led Telemedicine-Based Program for Patients with Heart Failure: The MAR-HF-Titration Study
This study evaluates the cost-effectiveness of the MAR-HF-Titration telemedicine programme, implemented at Hospital del Mar for patients with heart failure with reduced ejection fraction (HFrEF). A pre-post retrospective cost-effectiveness analysis was conducted using data from 208 patients enrolled between 2021 and 2023. Effectiveness was estimated by constructing individual pre- and post-intervention QALYs based on literature-derived utility values. Cost data were obtained from hospital administrative records at the patient level. Paired t-tests were performed, and costs and QALYs were modelled using gamma and beta distributions for probabilistic sensitivity analysis. A sensitivity analysis excluding newly diagnosed patients was also conducted. The programme was associated with a 52% reduction in total healthcare costs (€4,771.79 per patient), mainly driven by a reduction of the heart failure-related intervention costs, which accounted for 88% of total costs and decreased by 58% in the post-intervention period (€4,384.97 per patient). This reduction was also associated with a substantial decrease in length of stay during the post-intervention period, with a 76.63% reduction in total hospitalisations and an 82.34% reduction in hospitalisations related to heart failure. The effectiveness analysis showed an increase of 0.0298 QALYs per patient during the six-month intervention period. Similar outcomes were observed for non-newly diagnosed patients.
- 27 February 2026
- Published by MDPI AG in Preprints.org
Open AccessCost-Effectiveness of a Nurse-Led Telemedicine-Based Program for Patients with Heart Failure: The MAR-HF-Titration Study
This study evaluates the cost-effectiveness of the MAR-HF-Titration telemedicine programme, implemented at Hospital del Mar for patients with heart failure with reduced ejection fraction (HFrEF). A pre-post retrospective cost-effectiveness analysis was conducted using data from 208 patients enrolled between 2021 and 2023. Effectiveness was estimated by constructing individual pre- and post-intervention QALYs based on literature-derived utility values. Cost data were obtained from hospital administrative records at the patient level. Paired t-tests were performed, and costs and QALYs were modelled using gamma and beta distributions for probabilistic sensitivity analysis. A sensitivity analysis excluding newly diagnosed patients was also conducted. The programme was associated with a 52% reduction in total healthcare costs (€4,771.79 per patient), mainly driven by a reduction of the heart failure-related intervention costs, which accounted for 88% of total costs and decreased by 58% in the post-intervention period (€4,384.97 per patient). This reduction was also associated with a substantial decrease in length of stay during the post-intervention period, with a 76.63% reduction in total hospitalisations and an 82.34% reduction in hospitalisations related to heart failure. The effectiveness analysis showed an increase of 0.0298 QALYs per patient during the six-month intervention period. Similar outcomes were observed for non-newly diagnosed patients.